

Wednesday, 19 October 2022

2022 ANNUAL GENERAL MEETING RESULTS

In accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act* 2001, Australian Clinical Labs Limited (ASX:ACL)(**Company**) announces the outcome of each resolution put to shareholders at its Annual General Meeting, which was held today.

The following resolutions were passed on a poll, with full details of the number of votes and the total number of proxy votes appearing at Appendix A to this announcement:

1. Adoption of 2022 Remuneration Report
2. Re-election of Mr Andrew Dutton
3. Approval of the grant of performance rights to Ms Melinda McGrath

In respect of resolution 3, during the course of the AGM, the wording of the resolution that was put to shareholders was amended to read as follows (change shown in mark-up):

“That approval be given for the purposes of ASX Listing Rule 10.14, and for all other purposes, for the grant and issue of up to 286,624 Performance Rights to Ms Melinda McGrath, Chief Executive Officer and Executive Director of the Company, in relation to her LTVR for FY23, in accordance with the LTVR Plan and on the terms and conditions described in the explanatory memorandum accompanying this Notice of Meeting”

Shareholders who were unable to attend the AGM will find a recording of the Chair's and CEO's address on the Company's [website](#).

– ENDS –

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

Governance

Eleanor Padman

Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.



AUSTRALIAN CLINICAL LABS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING
Wednesday, 19 October, 2022

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	ADOPTION OF REMUNERATION REPORT	NA	136,188,651 99.78%	110,320 0.08%	195,307 0.14%	925,859	136,383,958 99.92%	110,320 0.08%	925,859	Carried
2	RE-ELECTION OF MR ANDREW DUTTON AS A DIRECTOR	NA	134,249,161 97.64%	3,056,339 2.22%	195,444 0.14%	19,090	134,444,605 97.78%	3,056,339 2.22%	19,090	Carried
3	APPROVAL OF GRANT OF PERFORMANCE RIGHTS TO MS MELINDA MCGRATH	NA	134,068,959 98.21%	2,246,527 1.65%	195,444 0.14%	909,207	134,122,146 98.25%	2,388,784 1.75%	909,207	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item